Please try another search
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Name | Age | Since | Title |
---|---|---|---|
Mary Mirabelli | 66 | 2021 | Non-Employee Independent Director |
James Lee Tyree | 70 | 2012 | Lead Independent Director |
Thomas J. Herzog | - | - | Member of Clinical Advisory Board |
Robert W. Holloway | - | - | Member of Clinical Advisory Board |
Alberto A. Mendivil | - | - | Member of Clinical Advisory Board |
John W. Smither | 70 | 2023 | Director |
Alan B. Forsythe | - | 2023 | Member of Clinical Advisory Board |
Robert L. Coleman | 62 | - | Member of Clinical Advisory Board |
David M. O’Malley | - | - | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review